Clinical Trials for Other Solid Tumor

Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients With Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This clinical trial investigates the use of CD40L-augmented tumor-infiltrating lymphocytes (TIL) combined with nivolumab for adults with stage IV or recurrent NSCLC harboring EGFR, ALK, ROS1, or HER2 mutations who have progressed following prior therapy. CD40L TIL are engineered to enhance immune response against cancer, while nivolumab blocks the PD-1 pathway, aiming to improve treatment outcomes in this patient population.

ClinicalTrials.gov ID: NCT05681780

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial investigates the efficacy of combining osimertinib, an EGFR-tyrosine kinase inhibitor, with bevacizumab, a VEGF inhibitor, versus osimertinib alone in treatment-naïve patients with advanced EGFR-mutant NSCLC. Eligible patients have EGFR-mutated NSCLC (stages IIIB-IV) with specific activating mutations.

ClinicalTrials.gov ID: NCT04181060

A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial targets patients with immunotherapy and chemotherapy naïve metastatic NSCLC with high PD-L1 TPS, EGFR and ALK mutation-negative disease, and detectable ctDNA, and investigates pembrolizumab alone or in combination with platinum-based chemotherapy.

ClinicalTrials.gov ID: NCT04093167

TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates the efficacy of adding atezolizumab, a PD-L1 inhibitor, to a regimen of carboplatin, pemetrexed, and bevacizumab in treating stage IV non-squamous NSCLC patients who harbor EGFR mutations or are never smokers with wild-type tumors lacking ALK or ROS1 rearrangements. The study compares outcomes between a treatment arm including the investigational drug atezolizumab and a standard treatment arm without it.

ClinicalTrials.gov ID: NCT03786692

Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves immunotherapy-naive patients with stage IV non-small cell lung cancer receiving treatment with nivolumab and ipilimumab, which are immune checkpoint inhibitors targeting PD-1 and CTLA-4, respectively; one group also receives local consolidation therapy to assess its impact on overall survival.

ClinicalTrials.gov ID: NCT03391869

A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial enrolls patients with advanced or recurrent non-small cell lung cancer having EGFR mutations and MET amplification, who progressed after osimertinib, to assess the efficacy of capmatinib (a MET inhibitor) and osimertinib with or without ramucirumab (an anti-angiogenic antibody).

ClinicalTrials.gov ID: NCT05642572

An Open-Label Phase I/II Study to Evaluate the Safety and prelimiBasnary Efficacy of Amivantamab and Tepotinib Combination in MET-altered Non-small Cell Lung Cancer (NSCLC)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with advanced MET-altered non-small cell lung cancer (NSCLC), specifically MET exon 14 skipping alterations or MET gene amplification, and evaluates the safety and efficacy of the combination treatment of amivantamab, a bispecific antibody targeting EGFR and c-MET, and tepotinib, an oral MET inhibitor.

ClinicalTrials.gov ID: NCT06083857

A Phase 1/2 Study of Oral MRT-2359 in Patients With MYC-Driven and Other Selected Solid Tumors Including Lung Cancer and Diffuse B-Cell Lymphoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: The trial involves patients with MYC-driven and selected solid tumors, including specific lung cancers and diffuse large B-cell lymphoma, who have limited treatment options, exploring the safety and efficacy of MRT-2359, a GSPT1 molecular glue degrader, both alone and in combination with fulvestrant or enzalutamide.

ClinicalTrials.gov ID: NCT05546268

A Phase Ib Dose De-Escalation Study of All-Trans Retinoic Acid (ATRA) and Atezolizumab in Patients With Advanced Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates the combination of all-trans retinoic acid (ATRA) and atezolizumab in adults with recurrent or metastatic non-small cell lung carcinoma who have prior experience with standard chemotherapy and/or immunotherapy. ATRA, affecting cellular growth and differentiation, is combined with atezolizumab, a PD-L1 inhibitor, to assess safety and preliminary efficacy in improving immune response against tumors.

ClinicalTrials.gov ID: NCT04919369

A Phase 2 Study of Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic Non-Small Cell Lung Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial investigates the efficacy of nivolumab, an immune checkpoint inhibitor targeting the PD-1 receptor, combined with ramucirumab, a VEGFR2 inhibitor, in patients with recurrent, advanced, metastatic non-small cell lung carcinoma who have previously received immunotherapy. It is specifically for patients treated with immunotherapy alone or with chemotherapy, regardless of PD-L1 status.

ClinicalTrials.gov ID: NCT03527108